BRISBANE, Calif. & ST. LOUIS--(BUSINESS WIRE)--Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced upcoming presentations at conferences and medical meetings:
Investor Conference:
Event: Stifel 2020 Annual Healthcare Conference
Date: November 17, 2020, 4:40 pm ET
Medical and Scientific Meetings:
Event: Macrophage-directed Therapies Summit 2020
Date: October 27-29, 2020
Event: CD47/SIRPα Summit 2020
Date: November 4-5, 2020
Event: SITC Annual Meeting 2020
Date: November 11-14, 2020
Abstract Title: AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
Event: PEGS Europe Virtual 2020
Date: November 9-13, 2020
About Arch Oncology
Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies. The Company’s next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class. Arch Oncology’s lead product candidate AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with multiple myeloma, both as monotherapy and in combination with standard therapies. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer. For more information please visit www.archoncology.com.
